You are here
Frequently Asked Questions (FAQ) - Innovative Medicines Initiative (IMI)
For topic 1 and 2: Sanofi (Coordinator), Novo Nordisk (Co-coordinator), Eli Lilly(To be confirmed), Other potential partners are still under consideration.
The topic of personalised medicine is central to many IMI projects, for an overview, please consult the IMI projects database at http://www.imi.europa.eu/content/ongoing-projects
The RADAR topic is still under discussion between the industrial partners in order to ensure the involvement of other industrial sectors such as the imaging companies.
The IMI Project COMBACTE deals with antimicrobial resistance (AMR) http://www.imi.europa.eu/content/combacte
According to the Horizon 2020 „minimum conditions“ for participation,(a) at least three legal entities shall participate in an action;(b) three legal entities shall each be established in a different Member State or associated country;c) the three legal entities referred to in point (b) shall be independent of each other
For this question, I would recommend to contact the Italian Delegate to the IMI States Represenatives Group, Giovina RUBERTI (grubertiAT ibc.cnr.it ). Furthermore, you can check all running IMI projects at http://www.imi.europa.eu/content/ongoing-projects
Partner search for the 1st IMI2 Call via: http://www.imi-partnering.de
In Germany only for stage 2, not for the EoI preparation
I suggest to check the IMI Newmeds project as an example: http://www.imi.europa.eu/content/newmeds
Call 9 has unfortunately already closed, but clinical trials can be funded within IMI projects